Skip to main content

Unicycive Therapeutics, Inc.

UNCY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001766140

No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $61.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Unicycive Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Unicycive Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Unicycive Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Kenkare-Mitra SaraDirector–Jul 28, 20261
Laumas SandeepDirector–Jul 28, 20261
Townsend JohnCFO–Jun 15, 20261
Gupta PramodEVP, Pharmaceuticals and BD41,845Jun 15, 20261
Gupta Shalabh K.CEO2,527,449Jun 15, 20261
Jermasek DouglasEVP, Corporate Strategy175,012Jun 15, 20261
Aggarwal GauravDirector1,789,915IndirectAug 26, 20250
Ryan John LDirector–Sep 7, 20230
Schiller BrigitteDirector15,000Apr 18, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 17, 2022 (view filing)May 161 daySchiller BrigitteDirectorPPurchase+15.0K$0.83+$12.4KNew position15.0K after